Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma
Starting soon · Phase 2
Conditions studied: Asthma (Diagnosis)
In brief
Acute asthma exacerbation is caused by dysregulated pulmonary inflammatory pathways such that standard treatment includes prompt administration of exogenous systemic corticosteroids (SCs), but there remains an ongoing dialogue among the expert medical community regarding the superiority of specific SCs including dose, frequency of administration, route, and delivery. Regimens are often chosen based on provider preference, and different strategies include once-daily dosing (ODD) dexamethasone (DM) 0.6 mg/kg/dose for 2 days, every 6 hours (q6h) DM 0.25 mg/kg/dose for 2 days, and methylprednisolone (MP) 1 mg/kg/dose every 6 hours for 5-days. To address this knowledge gap, the investigators plan to perform a single-center, phase 2, randomized clinical trial of children 3-17 years of age hospitalized for critical asthma (CA) randomized to one of three regimens above. The study would be powered to evaluate rates of additional prescriptions of SC and also secondarily evaluate quality of life metrics.
Key facts
- Study ID
- NCT07455396
- Run by
- Johns Hopkins All Children's Hospital
- People needed
- 159
- Starts
- 2026-08-01
- Expected to finish
- 2028-08-14
- Last updated by the study team
- 2026-07-15
Who can join
Age: 3 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 3-17 years
- Intensive care unit admission
- Treatment for critical asthma
You may not qualify if…
- History of unrepaired critical congenital heart disease
- History of cystic fibrosis
- Active tracheostomy dependence
Where it is running
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.